IGC Pharma Inc
For the period ended Dec 31, 2024. Filed Feb 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 14, 2025
IGC$0.20+2.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share data)
| December 31, 2024 ($) | March 31, 2024 ($) | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | 470 | 1,198 |
| Accounts receivable, net | 49 | 39 |
| Inventory | 1,433 | 1,540 |
| Asset held for sale | 701 | 720 |
| Deposits and advances | 398 | 208 |
| Total current assets | 3,051 | 3,705 |
| Non-current assets: | ||
| Intangible assets, net | 1,869 | 1,616 |
| Property, plant, and equipment, net | 3,348 | 3,695 |
| Claims and advances | 681 | 688 |
| Operating lease asset | 129 | 198 |
| Total non-current assets | 6,027 | 6,197 |
| Total assets | 9,078 | 9,902 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 835 | 773 |
| Accrued liabilities and others | 1,822 | 1,567 |
| Total current liabilities | 2,657 | 2,340 |
| Non-current liabilities: | ||
| Long-term loans | 134 | 137 |
| Other liabilities | 16 | 20 |
| Operating lease liability | 12 | 84 |
| Total non-current liabilities | 162 | 241 |
| Total liabilities | 2,819 | 2,581 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of December 31, 2024, and March 31, 2024. | ||
| Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 78,203,218 and 66,691,195 shares issued and outstanding as of December 31, 2024, and March 31, 2024, respectively. | 129,307 | 124,409 |
| Accumulated other comprehensive loss | (3,459) | (3,423) |
| Accumulated deficit | (119,589) | (113,665) |
| Total stockholders’ equity | 6,259 | 7,321 |
| Total liabilities and stockholders’ equity | 9,078 | 9,902 |
| December 31, 2024, Form 10-Q
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.